Drug research

ATI-450

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as CDD-450; Zunsemetinib

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)NCT05216224	ACRS	Phase 2	Completed	2022-12-23Actual
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)NCT04524858	ACRS	Phase 2	Terminated	2021-02-25Actual
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisNCT05511519	ACRS	Phase 2	Terminated	2023-12-06Actual

ACRSCompletedPrimary completion: 2022-12-23 · Actual

Trial details

ACRSTerminatedPrimary completion: 2021-02-25 · Actual

Trial details

ACRSTerminatedPrimary completion: 2023-12-06 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.